Currently funded projects

Dystrophin ∆52 lacks exon 52, which prohibits its expression as a protein. Additional excision of exon 51 restores the reading frame and expression of an internally truncated Dystrophin protein ∆51-52.

Genome editing as therapeutic approach to Duchenne´s muscle dystrophy

Institution: Klinikum Rechts der Isar, TU München
Applicant: Prof. Dr. med. Christian Kupatt

Ms. Kosanke preparing the real-time PCR reaction for the fast and accurate identification of pathogens causing dermatophytosis

A central service for the fast, accurate and sensitive detection of pathogens in suspected cases of dermatophytosis

Institution: Charité Berlin
Applicant: Prof. Dr. Yvonne Gräser

Syringe in lieu of mosquito: malaria sporozoites are prepared for the experimental infection.

Evaluation of the potential antimalarial effect of ivermectin: a controlled human malaria infection trial – PREMIVER (PREvention of Malaria with IVERmectin)

Institution: Institut für Tropenmedizin, Reisemedizin, Humanparasitologie, Universitätsklinikum Tübingen
Applicant: Prof. Dr. Peter G. Kremsner

Breeding of telocytes in cell culture. Telocytes will be characterized using biological methods, and cells with the best properties will be amplified by cultivation. Finally, “therapeutic telocytes” shall be used in the clinic.

Development of therapeutic cardiac telocytes to prevent heart failure after acute myocardial infarction

Institution: Kerkhoff-Klinik, Bad Nauheim
Applicant: PD Dr. Manfred Richter

CCL25 based regeneration for treatment of osteoarthritis. Concept of product design and application.

CCL25-based regeneration for treatment of osteoarthritis – Safety study on the biological factor CCL25

Institution: Labor für Tissue Engineering, Klinik für Rheumatologie und Klinische Immunologie, Charité – Universitätsmedizin Berlin
Applicant: Dr. rer. nat. Michael Sittinger

Optical Mapping of an intact Langendorff-perfused rabbit heart.

cardioLEAP - Low-Energy Anti-Fibrillation Pacing

Institution: Max-Planck-Institut für Dynamik und Selbstorganisation (MPIDS), Göttingen
Applicant: Prof. Dr. Stefan Luther

Mode of action of the HIV-1-specific recombinase Brec1. The viral genes (proviral DNA) are integrated into the host cell genome. Brec1 recombines the viral LTR sequences, and as a consequence, the viral genes are excised and degraded.

Anti-HIV gene-construct for CD34+ HSC gene therapy to cure HIV in HIV-associated diffuse large B-cell lymphoma (HIVCURE)

Institution: Heinrich-Pette-Institut,
Leibniz-Institut für Experimentelle Virologie
Applicant: Prof. Dr. rer. nat. Joachim Hauber

Prof. Dr. med. Paul Lingor, principal investigator of the clinical study funded by the EKFS

Inhibition of Rho kinase as a disease-modifying therapeutic strategy for neurodegenerative diseases

Institution: Klinikum rechts der Isar der Technischen Universität München
Universitätsmedizin Göttingen
Applicant: Prof. Dr. Paul Lingor

Production of oligomeric Avian flu antigens in leaves of Nicotiana benthamiana

Production of oligomeric Avian Flu vaccine candidates in planta and their practical verification

Institution: Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung (IPK), Gatersleben
Applicant: Prof. Dr. Udo Conrad

information grafic

Translational further development of a dense body-based vaccine against human cytomegalovirus infections

Institution: University Medical Center of the Johannes Gutenberg-University Mainz, Institute for Virology
Applicant: Prof. Dr. med. Bodo Plachter